drugset / Trial / NCT03266640
Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)
Phase 2
Recruiting
20 enrolled
New York Medical College
Children's Hospital Los Angeles · collabChildren's Hospital of Philadelphia · collabIndiana University · collabJohns Hopkins University · collabMedical College of Wisconsin · collabNationwide Children's Hospital · collabUniversity of California, San Francisco · collabWashington University School of Medicine · collab
NaSingle-groupOpen-labelTreatment
Summary
CMV cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults (CAYA) with refractory cytomegalovirus (CMV) infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD
Timeline
- Start
- 2018-11-01
- Primary completion
- 2026-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | viral specific cytotoxic t-lymphocytes | Unknown | 5000 cells/kg | — |
| Subject | viral specific cytotoxic t-lymphocytes | Unknown | 25000 cells/kg | — |